Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Inks $30M Credit Facility

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom said today that it and its Sequenom Center for Molecular Medicine have signed a $30 million credit facility with Silicon Valley Bank.

Sequenom plans to use funds from the facility to support the development and commercialization of new products and other near-term growth initiatives, it said.

The credit facility consists of a term loan of up to $20 million and a $10 million revolving line of credit. Sequenom said that it intends to use the line of credit to purchase capital equipment and expand laboratory capacity. It also will use the money to fund working capital requirements, accounts receivable, and inventory as Sequenom CMM prepares to commercialize and launch new laboratory-developed tests.

The San Diego-based molecular diagnostics firm hopes to launch its SensiGene Trisomy 21 laboratory-developed test either late this year or early next year.

"The addition of this new credit facility enables us to extend the runway provided by financings put in place over the last year and to maintain a consistent level of liquidity as we move into an active growth phase for the company, Sequenom CFO Paul Maier said in a statement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.